WAG
SGMO

Winthrop Advisory Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Winthrop Advisory Group’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,000
Closed -$8.66K – 169
2024
Q3 		$8.66K Hold
10,000
– – ﹤0.01% 152
2024
Q2 		$3.58K Hold
10,000
– – ﹤0.01% 144
2024
Q1 		$6.7K Hold
10,000
– – ﹤0.01% 141
2023
Q4 		$5.43K Hold
10,000
– – ﹤0.01% 139
2023
Q3 		$6K Hold
10,000
– – ﹤0.01% 126
2023
Q2 		$13K Hold
10,000
– – ﹤0.01% 132
2023
Q1 		$17.6K Hold
10,000
– – ﹤0.01% 128
2022
Q4 		$31.4K Hold
10,000
– – 0.01% 121
2022
Q3 		$49K Hold
10,000
– – 0.01% 114
2022
Q2 		$41K Hold
10,000
– – 0.01% 119
2022
Q1 		$58K Hold
10,000
– – 0.01% 136
2021
Q4 		$75K Hold
10,000
– – 0.02% 139
2021
Q3 		$90K Sell
10,000
-50
-0.5% -$494 0.02% 138
2021
Q2 		$120K Buy
10,050
+50
+0.5% +$566 0.03% 132
2021
Q1 		$125K Buy
+10,000
New +$135K 0.03% 132

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Winthrop Advisory Group's SGMO Position: Q4 2024 in Review

Winthrop Advisory Group sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2024, closing a stake of 10,000 shares — an estimated $8.66K sold.

Winthrop Advisory Group first reported a position in SGMO in Q1 2021 and held it in 15 quarters. The position peaked at $125K in Q1 2021. 128 funds tracked by Wall St. Rank hold SGMO as of Q4 2024.

  • Winthrop Advisory Group reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2024 after selling out during the quarter.
  • Winthrop Advisory Group sold 10,000 SANGAMO THERAPEUTICS INC shares in Q4 2024, an estimated $8.66K.
  • Winthrop Advisory Group first reported a position in SANGAMO THERAPEUTICS INC in Q1 2021 and held it in 15 quarters.
  • Winthrop Advisory Group's SANGAMO THERAPEUTICS INC position peaked at $125K in Q1 2021.
  • 128 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2024.

Based on Winthrop Advisory Group's 13F filing for Q4 2024, filed 13 Jan 2025.